Clinical trials

  • Mesenchymal stem cells for Stress urinary incontinence | Mixed urinary incontinence
  • RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN; RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN; RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN; OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B for Asplenia
  • DERMATOPHAGOIDES PTERONYSSINUS for Allergies
  • CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS for Postoperative atrial fibrillation | Atrial fibrillation
  • Doravirine for HIV-1 infection|HIV disease
  • URSODEOXYCHOLIC ACID for Hepatorenal polycystic diseases
  • PEMBROLIZUMAB for Glioblastoma
  • N. MENINGITIDIS GROUP C (STRAIN C11) POLYSACCHARIDE (DE-O-ACETYLATED) CONJUGATED TO TETANUS TOXOID; NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN; NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN; NEISSERIA MENINGITIDIS GROUP Y POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN for Invasive meningococcal disease | Sepsis | Meningitis
  • [18F]FLUORO-PEG-FOLATE for ACPA-positive arthralgia | Arthralgia
  • Lutetium-177 labelled 6A10 antibody Fab fragment for Glioblastoma|High-grade glioma
  • NIVOLUMAB for Pediatric solid tumor | Glioma | Brain tumor | Neuroblastoma | Rhabdomyosarcoma | Ependymoma | Ewing sarcoma | Lymphoma
  • NIVOLUMAB for Squamous cell carcinoma of the skin (locally advanced/metastatic)